Recombinant Human G-protein coupled receptor 20 (GPR20)

What is GPR20 and what are its key structural features?

GPR20 is a Class-A orphan G protein-coupled receptor comprising 358 amino acids that functions as a seven-pass transmembrane protein . The receptor exhibits a distinctive structural feature - a uniquely folded N-terminal helix that caps onto the transmembrane domain, which plays a critical role in its functional properties . GPR20 is notable for its constitutive activity, meaning it can activate G proteins in the absence of any known ligand stimulation . This constitutive activity primarily affects Gi proteins, leading to continuous activation that influences downstream signaling pathways . The receptor's amino acid sequence contains several conserved domains typical of GPCRs, with specific regions that determine its unique signaling properties and binding characteristics .

Where is GPR20 expressed in human tissues?

GPR20 shows a tissue-specific expression pattern, being predominantly expressed in the liver and certain regions of the brain . Within the brain, GPR20 expression is notably detected in the putamen, caudate nucleus, and thalamus, while expression is absent in the hypothalamus, pons, and frontal cortex . This selective distribution suggests region-specific functions in the central nervous system. Beyond normal tissues, GPR20 has gained significant research interest due to its differential high expression in gastrointestinal stromal tumors (GIST) . Expression analyses have demonstrated that GPR20 is detected in more than 80% of all GIST tumor samples, regardless of the number of prior tyrosine kinase inhibitor (TKI) treatments received . This consistent expression pattern across GIST samples has established GPR20 as a potential therapeutic target for these tumors.

How does GPR20's constitutive activity influence cellular function?

GPR20 exhibits high basal activity in the absence of ligand stimulation, which leads to continuous activation of its coupled Gi proteins . This constitutive activity has significant implications for intracellular signaling cascades. When exogenously expressed in HEK293 cells, GPR20 significantly decreases both basal and prostaglandin E2-induced production of cyclic adenosine monophosphate (cAMP) . Conversely, knockdown of GPR20 in PC12h cells results in elevated basal cAMP levels, confirming that endogenous GPR20 maintains a constitutively active conformation that suppresses cAMP production . This regulation of intracellular cAMP levels has broader implications for cellular processes, as cAMP is a critical second messenger that influences numerous physiological functions, including gene expression, cell proliferation, and differentiation . Additionally, the constitutive activity of GPR20 appears to play a role in mitogenic signaling pathways, potentially influencing cell growth and division .

What mechanisms underlie GPR20's constitutive activity?

Recent structural research using cryo-electron microscopy (cryo-EM) has revealed critical insights into GPR20's constitutive activity . Three key structures have been elucidated: Gi-coupled GPR20 with and without the Fab fragment of antibody Ab046, and Gi-free GPR20 . The most remarkable finding from these structural studies is the uniquely folded N-terminal helix that caps onto the transmembrane domain . Mutagenesis studies have demonstrated that this N-terminal cap region plays a crucial role in stimulating the basal activity of GPR20 . The structural configuration likely stabilizes the receptor in an active conformation, facilitating G protein coupling even without ligand binding. This structural arrangement represents a novel mechanism for constitutive activity among GPCRs and provides valuable insights for researchers studying receptor activation mechanisms. Understanding these structural determinants is essential for designing compounds that could modulate GPR20 activity for therapeutic purposes or experimental investigations.

What expression systems are optimal for producing recombinant GPR20?

Multiple expression systems have been successfully employed to produce recombinant human GPR20 for research applications. Cell-free protein synthesis (CFPS) systems have proven effective for generating recombinant GPR20, with systems such as ALiCE® (Almost Living Cell-Free Expression System) demonstrating success . This system, derived from Nicotiana tabacum lysate, contains the necessary protein expression machinery for producing challenging proteins like GPR20 that require post-translational modifications . HEK293 cells represent another widely used expression system for GPR20 production, offering mammalian post-translational modifications and proper membrane insertion . For structural studies, specialized approaches may be necessary to stabilize the receptor in specific conformations, particularly when investigating GPR20-G protein complexes . Purification strategies typically involve affinity tags such as His-tag or Strep-tag, with one-step purification protocols yielding GPR20 with purity levels typically >70-80% as determined by SDS-PAGE, Western Blot, and analytical SEC (HPLC) . Researchers should select an expression system based on their specific experimental requirements, considering factors such as required protein yield, desired post-translational modifications, and intended downstream applications.

How can researchers accurately assess GPR20 activity in experimental settings?

Given GPR20's constitutive activity, assessing its function requires specialized approaches that differ from traditional GPCR activity assays. Measurement of intracellular cAMP levels serves as a primary method for evaluating GPR20 activity, as the receptor constitutively suppresses cAMP production through Gi protein activation . Both basal cAMP levels and changes in response to potential modulators should be quantified. Comparative analyses between wild-type cells and those with GPR20 knockdown or overexpression can provide valuable insights into the receptor's contribution to cellular signaling . For structure-function studies, mutagenesis approaches targeting the N-terminal cap region have proven informative in understanding the molecular determinants of GPR20's constitutive activity . Researchers should implement both gain-of-function and loss-of-function mutations to comprehensively characterize the receptor's activation mechanisms. Additionally, co-immunoprecipitation assays to detect GPR20-G protein interactions and bioluminescence resonance energy transfer (BRET) techniques can provide direct evidence of receptor-effector coupling efficiency in both basal and stimulated conditions.

Why has GPR20 emerged as a therapeutic target for gastrointestinal stromal tumors (GIST)?

GPR20 has emerged as a promising therapeutic target for GIST due to several key characteristics that make it particularly suitable for targeted therapy approaches. First, GPR20 is selectively and abundantly expressed in GIST, with detection in more than 80% of all GIST tumor samples . This expression remains consistent regardless of the number of prior tyrosine kinase inhibitor (TKI) treatments received, making it a reliable target even in treatment-resistant cases . Unlike many other potential targets, GPR20 expression is maintained across different GIST genotypes, including those with mutations in KIT and/or PDGFRA as well as wild-type variants . This broad expression pattern allows GPR20-targeted therapies to potentially address a wide spectrum of GIST cases, including those with limited treatment options. The selective expression profile of GPR20, being highly expressed in GIST while showing restricted expression in normal tissues, creates a favorable therapeutic window that may minimize off-target effects . These characteristics collectively establish GPR20 as an attractive target for novel therapeutic approaches, particularly antibody-drug conjugates (ADCs) that can exploit the differential expression pattern.

What clinical approaches are being developed to target GPR20 in GIST?

The most advanced clinical approach targeting GPR20 in GIST is DS-6157a, an antibody-drug conjugate (ADC) developed by Daiichi Sankyo . DS-6157a comprises a humanized anti-GPR20 monoclonal antibody covalently conjugated to an enzymatically cleavable linker and a novel exatecan derivative (DXd) payload . This innovative therapeutic underwent a Phase I, multicenter, open-label, first-in-human study in patients with previously treated advanced GIST . The clinical trial featured a two-part design: the first part (dose escalation) assessed safety and tolerability of increasing doses to determine the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) . This portion enrolled approximately 40 patients with advanced/unresectable or metastatic GIST who had progressed on or were intolerant to imatinib and other TKI treatments . The second part (dose expansion) evaluated safety, tolerability, and efficacy at the established RDE, including two cohorts - one with approximately 30 patients who had progressed on imatinib and at least one post-imatinib treatment . Initial clinical results showed that DS-6157a was well tolerated, with an adverse event profile comparable to other DXd-ADC therapies, and demonstrated preliminary efficacy with tumor shrinkage observed in 7 of 34 patients enrolled .

How does GPR20 expression correlate with different molecular subtypes of GIST?

Research on the relationship between GPR20 expression and specific molecular subtypes of GIST has revealed interesting patterns that may inform targeted therapy approaches. GPR20 expression has been detected across diverse GIST genotypes, including tumors with mutations in KIT and/or PDGFRA as well as wild-type variants, making it a broadly applicable therapeutic target . Preliminary clinical data from the DS-6157a trial indicated that response to GPR20-targeted therapy might vary among molecular subtypes . Notably, one patient with succinate dehydrogenase-deficient GIST harboring an NF1 mutation (wild-type KIT/PDGFRA) achieved a partial response to treatment . This observation suggests that certain molecular subtypes might be particularly sensitive to GPR20-targeted approaches, although comprehensive correlation analyses are still needed. The median GPR20 H-score among patients in the clinical trial was 168 (range, 12–273), indicating variability in expression levels that could potentially influence therapeutic response . These findings underscore the importance of further investigating the relationship between response to GPR20-targeted therapy and specific molecular subtypes of GIST, which may ultimately guide patient selection and therapeutic decision-making.

What methods are recommended for producing functional recombinant GPR20 for research?

Production of functional recombinant GPR20 requires careful consideration of expression systems and purification strategies to maintain the protein's native conformation and activity. Several approaches have proven successful for different research applications:

For optimal results, researchers should consider incorporating synthetic nanodiscs or other membrane mimetics when working with purified GPR20 to maintain its native conformation . Addition of stabilizing agents during purification can help preserve the receptor's functional state, particularly important given its constitutive activity . Quality control should include multiple analytical methods such as SDS-PAGE, Western blotting, and analytical size exclusion chromatography (SEC) to confirm proper folding and homogeneity . For applications requiring higher purity (>90%), additional chromatography steps beyond initial affinity purification may be necessary . Researchers should validate the functionality of recombinant GPR20 preparations through activity assays measuring effects on cAMP levels or G protein coupling before proceeding to specialized experiments.

How can researchers effectively use GPR20 control fragments in their experiments?

Control fragments of GPR20, such as the human GPR20 (aa 307-356) control fragment recombinant protein, offer valuable tools for validating experimental results and optimizing assay conditions . These control fragments are particularly useful for blocking experiments to confirm antibody specificity . When conducting immunohistochemistry (IHC), immunocytochemistry (ICC), or Western blot (WB) experiments, researchers should pre-incubate the antibody with a 100x molar excess of the protein fragment control for 30 minutes at room temperature before application to the sample . This blocking approach helps distinguish between specific and non-specific antibody binding, significantly enhancing the reliability of experimental results. Control fragments can also serve as positive controls in assays detecting GPR20, establishing a reference signal for comparison with experimental samples . For cross-species studies, it's important to note the sequence homology between human GPR20 control fragments and orthologs from other species—for example, the human GPR20 (aa 307-356) fragment shows 67% sequence identity to both mouse and rat orthologs . This information helps researchers anticipate potential cross-reactivity when using these reagents across different model systems. Through careful implementation of these control strategies, researchers can significantly improve the rigor and reproducibility of their GPR20-focused investigations.

What recent structural insights have advanced our understanding of GPR20?

Recent cryo-electron microscopy (cryo-EM) studies have provided groundbreaking structural insights into GPR20, significantly advancing our understanding of this orphan receptor . Three critical structures have been elucidated: Gi-coupled GPR20 both with and without the Fab fragment of antibody Ab046, and Gi-free GPR20 . These structures revealed a previously unknown feature—a uniquely folded N-terminal helix that caps onto the transmembrane domain . Subsequent mutagenesis studies demonstrated that this cap region plays a key role in stimulating the basal activity of GPR20, providing a structural explanation for the receptor's constitutive activity . This finding represents a novel activation mechanism among GPCRs and expands our understanding of how receptors can achieve high basal activity in the absence of known ligands. These structural insights have important implications for drug discovery, as they identify specific structural elements that could be targeted to modulate GPR20 activity. The structural data also illuminate the antibody binding mode for GPR20, providing valuable information for the rational design of therapeutic antibodies with improved binding properties or specific functional effects. As research continues, these structural foundations will likely guide the development of small molecule modulators or biologics targeting specific conformational states of GPR20.

What research questions remain unanswered about GPR20?

Despite significant advances in GPR20 research, several important questions remain unanswered that represent fertile ground for future investigations. The potential existence of endogenous ligands for GPR20 remains an open question—although the receptor exhibits constitutive activity, this does not preclude the existence of endogenous modulators that might enhance or inhibit its activity under specific physiological conditions . The physiological role of GPR20 in normal tissues, particularly in the liver and specific brain regions where it is expressed, remains poorly understood and warrants further investigation . While GPR20's involvement in regulating cAMP levels and mitogenic signaling has been established, the complete signaling repertoire of the receptor, including potential G protein-independent pathways, requires further characterization . The molecular mechanisms that regulate GPR20 expression in both normal tissues and pathological conditions like GIST remain largely unexplored, despite their potential therapeutic significance. Additionally, although GPR20 is being investigated as a therapeutic target for GIST, its potential involvement in other malignancies or disorders has not been thoroughly examined. Further research is also needed to determine why certain molecular subtypes of GIST might be particularly responsive to GPR20-targeted therapies, as suggested by early clinical data . Addressing these questions will not only advance our fundamental understanding of GPR20 biology but could also open new avenues for therapeutic intervention.

How might advances in GPR20 research impact future therapeutic developments?

The expanding knowledge of GPR20 biology, structure, and function promises to influence therapeutic developments across several domains. The selective expression of GPR20 in GIST tumors across different genotypes positions it as a valuable target for developing therapies that could address treatment-resistant cases . Current clinical investigation of DS-6157a, the GPR20-directed antibody-drug conjugate, represents just the beginning of potential therapeutic applications . If successful, this approach could establish a new paradigm for targeting orphan GPCRs with differential expression in cancer. The structural elucidation of GPR20's unique N-terminal cap and its role in constitutive activity provides specific molecular targets for developing small molecule modulators that could fine-tune GPR20 signaling . Such compounds could serve as valuable research tools and potentially lead to novel therapeutic strategies beyond antibody-drug conjugates. As researchers further characterize the relationship between specific GIST molecular subtypes and response to GPR20-targeted therapies, opportunities for precision medicine approaches may emerge, allowing treatments to be tailored to patients most likely to benefit . Beyond GIST, exploration of GPR20's role in other malignancies or disorders could expand the therapeutic relevance of this receptor to additional disease states. Furthermore, insights gained from understanding GPR20's constitutive activity mechanism might be applicable to other orphan GPCRs, potentially accelerating drug discovery for these traditionally challenging targets. Together, these advances suggest that GPR20 research will continue to yield important basic insights while simultaneously driving therapeutic innovation.